Royalty Report: Drugs, Disease, cardiac – Collection: 263908

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Disease
  • cardiac
  • Therapeutic
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 263908

License Grant
The Licensor of Sweden  grants an exclusive license in the Territory under the Licensor IP to perform research on, have research performed on, develop, have developed, use, have used, make, have made, import, have imported, market, have marketed, sell and have sold the Compound and the Product for all indications.
License Property
Licensor performs research, development and marketing of pharmaceutical compounds and products inter alia in the cardiovascular therapy area; and has developed the intravenous product Clevidipine.

The Chemical name for Clevidipine is  Butyroxymethyl methyl 4-(2 ,3 -dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate.

The patents include Short acting dihydropyridines and Pharmaceutical emulsion.

Clevidipine is a dihydropyridine calcium channel blocker indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable.

Field of Use
The field of use is in the cardiovascular therapy area, for indications such as the control of blood pressure.

IPSCIO Record ID: 264981

License Grant
For the rights granted for Japan, Licensor grants to the Licensee of Sweden a sub-licensable non-exclusive license under the Licensor IP to perform research on, have research performed on, develop, have developed, use, have used, make, have made, import, have imported, market, have marketed, sell and have sold the Compound and the Product for all indications in Japan.

Should Licensor have selected the Licensor Trademark, in the Territory, then the license shall include an exclusive right and license for Licensee to utilize the Licensor Trademark in Japan.

License Property
The Chemical is Clevidipine or  Butyroxymethyl methyl 4-(2 ,3 -dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate.
Field of Use
The field of use is in the cardiovascular therapy area, for indications such as the control of blood pressure.

IPSCIO Record ID: 2719

License Grant
Seller shall sell, transfer, assign, convey, deliver, license or sublicense, as specified below, to Buyer, or shall cause to be sold, transferred, assigned, conveyed, delivered, licensed or sublicensed, as specified below, to Buyer, and Buyer shall acquire all of Seller’s right, title and interest in and to the properties and assets of Seller.
Field of Use
The Licensee would acquire all rights to the cardiovascular products, including related trademarks, patents, intellectual property, product inventory and other related assets consisting of Cardene® I.V. (nicardipine hydrochloride), Cardene SR® and new formulations of Cardene in development, as well as Retavase® (reteplase) and the development product ularitide.  Cardene®  is for the short-term treatment of hypertension when oral therapy is not feasible or desirable. Cardene I.V. is the only intravenous calcium channel blocker (calcium ion influx inhibitor) for this indication.  Cardene I.V. offers rapid, precise blood pressure control and has been proven to be as effective as sodium nitroprusside with fewer dose adjustments (1).  Cardene I.V. prevents calcium ions from entering cardiac and vascular smooth muscle cells (the cells that line the arteries) through specific ion channels in the cell membrane. When these channels are blocked, calcium cannot enter the cell, thereby preventing the vascular smooth muscle from contracting.  Retavase® (reteplase) is a fibrinolytic agent for the management of acute myocardial infarction (AMI) or heart attack in adults for the improvement of ventricular function following AMI, the reduction of the incidence of congestive heart failure and the reduction of mortality associated with AMI. Treatment. Retavase, a recombinant plasminogen activator, works by generating plasmin, an enzyme produced naturally by the body’s blood plasma. Plasmin breaks down fibrin, a major constituent of blood clots, thereby helping to dissolve the clots.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.